Physician profile
Peter B Wagner
NPI 1598734196
$956.88
in general payments reported to CMS, 2019-2025
12 companies · $259 in 2025
The $259 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $514 · 2020: $31.94 · 2023: $39.24 · 2024: $113 · 2025: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $411.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $280.16 | 2019-2024 | |
| Corvista Health, INC. | $212.54 | 2025 | Corvista System |
| Boston Scientific Corporation | $174.63 | 2019-2023 | Resonate El Icd Vr |
| Amgen INC. | $91.05 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $53.31 | 2019-2024 | Eliquis |
| Gilead Sciences, INC. | $41.40 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $38.64 | 2019 | |
| Sanofi-Aventis U.S. LLC | $22.73 | 2019 | |
| Arbor Pharmaceuticals, INC. | $18.22 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $12.43 | 2019 | |
| Amarin Pharma, INC. | $11.77 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Wagner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.